Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

InflaRx N.V. IFRX

Healthcare  —  Biotechnology
1.89 (0.04) (2.07%) as of 25 Sep
Market cap
$284.4M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

InflaRx N.V. (IFRX) Business Profile

Updated before January 2025

Company Overview

InflaRx N.V. (NASDAQ: IFRX) is a clinical-stage biopharmaceutical company headquartered in Jena, Germany. Founded in 2007 by Dr. Niels Riedemann, Dr. Renfeng Guo, and Dr. Klaus Gerwert, the company focuses on discovering and developing first-in-class anti-inflammatory therapeutics by targeting the complement system, a key component of the immune system. InflaRx is particularly recognized for its expertise in the C5a pathway, which plays a critical role in inflammatory diseases. The company is led by Dr. Niels Riedemann, who serves as the Chief Executive Officer, and supported by a team of experienced executives and scientists with deep expertise in immunology and drug development.

InflaRx operates with a mission to address unmet medical needs in the treatment of severe and life-threatening inflammatory diseases. The company has a global presence, with operations in Europe and the United States, and collaborates with leading academic institutions and industry partners to advance its research and development efforts.

Core Business Segments

InflaRx’s core business revolves around the development of innovative therapeutics targeting the complement system. The company’s primary focus is on the following product categories:

1. Monoclonal Antibodies

  • Vilobelimab (IFX-1): InflaRx’s lead product candidate, vilobelimab, is a first-in-class anti-C5a monoclonal antibody. It is being developed for multiple indications, including hidradenitis suppurativa (HS), a chronic inflammatory skin disease, and severe COVID-19-induced acute respiratory distress syndrome (ARDS). Vilobelimab has shown promising results in clinical trials, demonstrating its potential to reduce inflammation and improve patient outcomes.

2. Complement System Modulators

  • InflaRx is actively exploring additional therapeutic candidates targeting the complement system. These include preclinical and early-stage development programs aimed at addressing other inflammatory and autoimmune diseases.

3. Pipeline Expansion

  • The company is committed to expanding its pipeline by identifying new targets within the complement system and developing innovative therapies to address a broader range of diseases.

Business Model

InflaRx operates as a research-driven biopharmaceutical company with a focus on innovation and clinical development. The company’s business model is centered around the following key elements:

  • Research and Development (R&D): InflaRx invests heavily in R&D to discover and develop novel therapeutics targeting the complement system. The company collaborates with academic institutions and industry partners to leverage cutting-edge science and technology.

  • Clinical Trials: InflaRx conducts rigorous clinical trials to evaluate the safety and efficacy of its product candidates. The company’s clinical development strategy is designed to accelerate the path to regulatory approval and commercialization.

  • Partnerships and Licensing: InflaRx seeks strategic partnerships and licensing agreements to advance its product candidates and expand its market reach. These collaborations provide access to additional resources and expertise.

  • Revenue Generation: As a clinical-stage company, InflaRx does not yet generate significant revenue from product sales. The company relies on funding from investors, grants, and partnerships to support its operations and development programs.

Strategic Direction

InflaRx is focused on achieving the following strategic objectives:

  • Advancing Vilobelimab: The company aims to complete ongoing clinical trials for vilobelimab and secure regulatory approvals for its use in multiple indications. InflaRx is also exploring additional therapeutic applications for vilobelimab.

  • Expanding the Pipeline: InflaRx is committed to identifying new targets within the complement system and developing innovative therapies to address unmet medical needs in inflammatory and autoimmune diseases.

  • Global Market Expansion: The company plans to expand its presence in key markets, including North America, Europe, and Asia, to maximize the commercial potential of its product candidates.

  • Sustainability Goals: InflaRx is dedicated to conducting its operations in an environmentally and socially responsible manner. The company aims to minimize its environmental footprint and contribute to the well-being of patients and communities.

Competitive Landscape

InflaRx operates in a highly competitive biopharmaceutical industry, where it faces competition from both established companies and emerging players. Key competitors include:

  • Alexion Pharmaceuticals (AstraZeneca): A leader in complement system therapeutics, Alexion develops treatments for rare diseases, including Soliris and Ultomiris.
  • Apellis Pharmaceuticals: Focused on complement system modulation, Apellis develops therapies for rare and chronic diseases, including pegcetacoplan.
  • Other Biopharmaceutical Companies: InflaRx also competes with companies developing therapies for inflammatory and autoimmune diseases, such as Regeneron, Roche, and Novartis.

Risk Factors

InflaRx faces several risks that could impact its business and operations:

  • Regulatory Risks: The company’s product candidates must undergo rigorous regulatory review before they can be approved for commercialization. Delays or failures in obtaining regulatory approvals could impact InflaRx’s growth prospects.
  • Market Dependence: As a clinical-stage company, InflaRx relies heavily on the success of its lead product candidate, vilobelimab. Any setbacks in its development or commercialization could adversely affect the company.
  • Supply Chain Disruptions: InflaRx depends on third-party suppliers and manufacturers for the production of its product candidates. Disruptions in the supply chain could delay clinical trials and commercialization efforts.
  • Financial Risks: The company’s operations are capital-intensive, and it may require additional funding to support its R&D and clinical development programs.

Recent Developments

  • COVID-19 Research: InflaRx has been actively involved in developing vilobelimab as a potential treatment for severe COVID-19-induced ARDS. The company has reported positive results from clinical trials and is working towards regulatory approval.
  • Pipeline Progress: InflaRx continues to advance its pipeline, with several preclinical and early-stage development programs targeting the complement system.
  • Strategic Partnerships: The company has entered into collaborations with academic institutions and industry partners to accelerate its research and development efforts.

Investment Considerations

Strengths:

  • Strong focus on innovation and expertise in the complement system.
  • Promising clinical data for vilobelimab and other product candidates.
  • Experienced leadership team and robust R&D capabilities.
  • Strategic partnerships and collaborations to support growth.

Risks:

  • Dependence on the success of vilobelimab for future growth.
  • Regulatory and clinical development risks.
  • Financial challenges associated with being a clinical-stage company.
  • Competitive pressures from established players and emerging competitors.

Conclusion

InflaRx N.V. is a pioneering biopharmaceutical company with a strong focus on developing innovative therapies targeting the complement system. With its lead product candidate, vilobelimab, and a robust pipeline, the company is well-positioned to address unmet medical needs in inflammatory and autoimmune diseases. While InflaRx faces challenges associated with being a clinical-stage company, its commitment to innovation, strategic partnerships, and global market expansion provide a solid foundation for future growth. Investors should carefully consider the company’s strengths and risks when evaluating it as a potential investment opportunity.